KalVista Pharmaceuticals (NASDAQ:KALV) Reaches New 12-Month High – What’s Next?

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) reached a new 52-week high during mid-day trading on Monday . The stock traded as high as $26.98 and last traded at $26.9750, with a volume of 210621 shares traded. The stock had previously closed at $26.95.

Analyst Ratings Changes

Several analysts have issued reports on the stock. Leerink Partners lowered shares of KalVista Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, April 29th. Weiss Ratings restated a “sell (d-)” rating on shares of KalVista Pharmaceuticals in a research report on Tuesday, April 21st. JonesTrading lowered shares of KalVista Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Thursday, April 30th. Citizens Jmp lowered shares of KalVista Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, April 29th. Finally, HC Wainwright lowered shares of KalVista Pharmaceuticals from a “buy” rating to a “neutral” rating and decreased their price target for the stock from $37.00 to $27.00 in a research report on Friday, May 1st. Three research analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $30.60.

KalVista Pharmaceuticals Price Performance

The business’s fifty day moving average price is $23.71 and its 200 day moving average price is $18.54. The company has a market capitalization of $1.44 billion, a P/E ratio of -7.80 and a beta of -0.12. The company has a current ratio of 5.17, a quick ratio of 5.10 and a debt-to-equity ratio of 8.18.

KalVista Pharmaceuticals (NASDAQ:KALV) last released its quarterly earnings data on Thursday, May 14th. The specialty pharmaceutical company reported ($0.43) EPS for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.05). The firm had revenue of $40.86 million for the quarter, compared to the consensus estimate of $39.03 million. As a group, equities research analysts predict that KalVista Pharmaceuticals, Inc. will post -1.19 earnings per share for the current fiscal year.

Insider Activity

In related news, major shareholder Venrock Healthcare Capital Par sold 174,645 shares of KalVista Pharmaceuticals stock in a transaction dated Wednesday, March 25th. The shares were sold at an average price of $16.95, for a total transaction of $2,960,232.75. Following the completion of the transaction, the insider directly owned 5,129,340 shares of the company’s stock, valued at $86,942,313. This trade represents a 3.29% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Paul K. Audhya sold 2,686 shares of KalVista Pharmaceuticals stock in a transaction dated Friday, April 17th. The shares were sold at an average price of $20.22, for a total transaction of $54,310.92. Following the transaction, the insider directly owned 142,547 shares of the company’s stock, valued at $2,882,300.34. This represents a 1.85% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold a total of 254,602 shares of company stock worth $4,656,670 over the last ninety days. Corporate insiders own 4.30% of the company’s stock.

Institutional Investors Weigh In On KalVista Pharmaceuticals

Hedge funds and other institutional investors have recently bought and sold shares of the business. Tudor Investment Corp ET AL acquired a new stake in KalVista Pharmaceuticals during the 3rd quarter valued at $24,360,000. Jefferies Financial Group Inc. acquired a new stake in KalVista Pharmaceuticals during the 3rd quarter valued at $3,494,000. Blue Owl Capital Holdings LP acquired a new stake in KalVista Pharmaceuticals during the 3rd quarter valued at $1,522,000. Hennion & Walsh Asset Management Inc. increased its holdings in KalVista Pharmaceuticals by 93.6% during the 4th quarter. Hennion & Walsh Asset Management Inc. now owns 341,819 shares of the specialty pharmaceutical company’s stock valued at $5,520,000 after purchasing an additional 165,236 shares in the last quarter. Finally, F m Investments LLC raised its stake in shares of KalVista Pharmaceuticals by 18.8% in the fourth quarter. F m Investments LLC now owns 236,690 shares of the specialty pharmaceutical company’s stock worth $3,823,000 after acquiring an additional 37,486 shares during the last quarter.

KalVista Pharmaceuticals Company Profile

KalVista Pharmaceuticals is a clinical‐stage biotechnology company focused on the discovery and development of small‐molecule protease inhibitors for orphan and specialty disease indications. The firm’s scientific platform centers on selective inhibition of plasma kallikrein, a serine protease implicated in disorders characterized by vascular leak, edema and inflammation. KalVista’s approach leverages oral and intravitreal delivery formats to target both systemic and ophthalmic conditions.

The company’s lead programs include an oral plasma kallikrein inhibitor in clinical trials for the acute treatment of hereditary angioedema (HAE) attacks and an intravitreal kallikrein inhibitor being evaluated for diabetic macular edema.